よむ、つかう、まなぶ。
総－３ー１最適使用推進ガイドライン チルゼパチド ［793KB］ (27 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_53715.html |
| 出典情報 | 中央社会保険医療協議会 総会（第605回 3／12）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
i
ii
iii
iv
v
vi
vii
viii
ix
x
xi
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of
co-morbidities related to obesity and overweight: a systematic review and meta-analysis.
BMC Public Health. 2009;9:88.
World Health Organization. Obesity: Preventing and Managing the Global Epidemic.
Report of a WHO Consultation. World Health Organisation Geneva, Switzerland. 2000.
Prospective Studies C, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al.
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of
57 prospective studies. Lancet. 2009;373(9669):1083-96.
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden
associated with overweight and obesity. JAMA. 1999;282(16):1523-9.
Saab J, Salvatore SP. Evaluating the cause of death in obese individuals: a ten-year
medical autopsy study. J Obes. 2015;695374.
厚生労働省健康局. 令和 4 年国民健康・栄養調査結果の概要. 2024 年 8 月.
https://www.mhlw.go.jp/content/10900000/001296359.pdf
日本肥満学会. 肥満症診療ガイドライン. ライフサイエンス出版. 2022 年 12 月
The Examination Committee of Criteria for ‘Obesity Disease’ in Japan. New Criteria for
‘Obesity Disease’ in Japan. Circ J. 2002;66(11):987-92.
Costa A, Ai M, Nunn N, Culotta I, Hunter J, Boudjadja MB, Valencia-Torres L, Aviello G,
Hodson DJ, Snider BM, Coskun T, Emmerson PJ, Luckman SM, D'Agostino G. Anorectic
and aversive effects of GLP-1 receptor agonism are mediated by brainstem
cholecystokinin neurons, and modulated by GIP receptor activation. Mol Metab. 2022
Jan;55:101407.
Moura-Assis A, Friedman JM, Velloso LA. Gut-to-brain signals in feeding control. Am J
Physiol Endocrinol Metab. 2021 Feb 1;320(2):E326-E332.
Regmi A, Aihara E, Christe ME, Varga G, Beyer TP, Ruan X, Beebe E, O'Farrell LS,
Bellinger MA, Austin AK, Lin Y, Hu H, Konkol DL, Wojnicki S, Holland AK, Friedrich
JL, Brown RA, Estelle AS, Badger HS, Gaidosh GS, Kooijman S, Rensen PCN, Coskun T,
Thomas MK, Roell W. Tirzepatide modulates the regulation of adipocyte nutrient
metabolism through long-acting activation of the GIP receptor. Cell Metab. 2024 Jul
2;36(7):1534-1549.e7.
26
ii
iii
iv
v
vi
vii
viii
ix
x
xi
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of
co-morbidities related to obesity and overweight: a systematic review and meta-analysis.
BMC Public Health. 2009;9:88.
World Health Organization. Obesity: Preventing and Managing the Global Epidemic.
Report of a WHO Consultation. World Health Organisation Geneva, Switzerland. 2000.
Prospective Studies C, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al.
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of
57 prospective studies. Lancet. 2009;373(9669):1083-96.
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden
associated with overweight and obesity. JAMA. 1999;282(16):1523-9.
Saab J, Salvatore SP. Evaluating the cause of death in obese individuals: a ten-year
medical autopsy study. J Obes. 2015;695374.
厚生労働省健康局. 令和 4 年国民健康・栄養調査結果の概要. 2024 年 8 月.
https://www.mhlw.go.jp/content/10900000/001296359.pdf
日本肥満学会. 肥満症診療ガイドライン. ライフサイエンス出版. 2022 年 12 月
The Examination Committee of Criteria for ‘Obesity Disease’ in Japan. New Criteria for
‘Obesity Disease’ in Japan. Circ J. 2002;66(11):987-92.
Costa A, Ai M, Nunn N, Culotta I, Hunter J, Boudjadja MB, Valencia-Torres L, Aviello G,
Hodson DJ, Snider BM, Coskun T, Emmerson PJ, Luckman SM, D'Agostino G. Anorectic
and aversive effects of GLP-1 receptor agonism are mediated by brainstem
cholecystokinin neurons, and modulated by GIP receptor activation. Mol Metab. 2022
Jan;55:101407.
Moura-Assis A, Friedman JM, Velloso LA. Gut-to-brain signals in feeding control. Am J
Physiol Endocrinol Metab. 2021 Feb 1;320(2):E326-E332.
Regmi A, Aihara E, Christe ME, Varga G, Beyer TP, Ruan X, Beebe E, O'Farrell LS,
Bellinger MA, Austin AK, Lin Y, Hu H, Konkol DL, Wojnicki S, Holland AK, Friedrich
JL, Brown RA, Estelle AS, Badger HS, Gaidosh GS, Kooijman S, Rensen PCN, Coskun T,
Thomas MK, Roell W. Tirzepatide modulates the regulation of adipocyte nutrient
metabolism through long-acting activation of the GIP receptor. Cell Metab. 2024 Jul
2;36(7):1534-1549.e7.
26